Research Papers:
Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2296 views | HTML 2334 views | ?
Abstract
Koji Shindo1, Jun Yu1, Masaya Suenaga1, Shahriar Fesharakizadeh1, Koji Tamura1, Jose Alejandro Navarro Almario1, Aaron Brant1, Michael Borges1, Abdulrehman Siddiqui1, Lisa Datta4, Christopher L. Wolfgang2, Ralph H. Hruban1, Alison Patricia Klein3,5 and Michael Goggins1,3,4
1Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
2Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
3Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
4Department of Medicine, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
5Department of Epidemiology, Bloomberg School of Public Health, Baltimore, Maryland, USA
Correspondence to:
Michael Goggins, email: [email protected]
Keywords: CEL, CELP, CEL-HYB, pancreatic cancer, chronic pancreatitis
Received: November 14, 2016 Accepted: January 01, 2017 Published: February 07, 2017
ABSTRACT
CEL-HYB is a hybrid allele that arose from a crossover between the 3’ end of the Carboxyl ester lipase (CEL) gene and the nearby CEL pseudogene (CELP) and was recently identified as a risk factor for chronic pancreatitis. Since chronic pancreatitis is a risk factor for the development of pancreatic cancer, we compared the prevalence of the CEL-HYB allele in patients with pancreatic ductal adenocarcinoma to spousal controls and disease controls. The CEL-HYB allele was detected using Sanger and next generation sequencing. There was no significant difference in the prevalence of the CEL-HYB allele between cases with pancreatic ductal adenocarcinoma compared to controls; 2.6% (22/850) vs. 1.8% (18/976) (p=0.35). CEL-HYB carriers were not more likely to report a history of pancreatitis. Patients with pancreatic cancer are not more likely than controls to be carriers of the CEL-HYB allele.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15137